Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb:55:136.
doi: 10.1016/j.breast.2020.11.017. Epub 2020 Nov 30.

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?

Atul Batra  1 , Akash Kumar  2
Affiliations
Comment

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?

Atul Batra et al. Breast. 2021 Feb.
No abstract available

Keywords: Breast cancer; HER2; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest All the authors declare no competing conflict of interest relevant to this research article.

Comment in

Comment on

References

    1. Li S., Wu J., Huang O., He J., Zhu L., Chen W. HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab. Breast. 2020 doi: 10.1016/j.breast.2020.10.002. - DOI - PMC - PubMed
    1. Rydén L., Landberg G., Stål O., Nordenskjöld B., Fernö M., Bendahl P.-O. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Canc Res Treat. 2008;109:351–357. doi: 10.1007/s10549-007-9660-2. - DOI - PubMed
    1. García Fernández A., Giménez N., Fraile M., González S., Chabrera C., Torras M. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning. Breast. 2012;21:366–373. doi: 10.1016/j.breast.2012.03.004. - DOI - PubMed
    1. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96:926–935. doi: 10.1093/jnci/djh166. - DOI - PubMed